STOCK TITAN
  1. Home
  2. Sec-filings
  3. MREO
  4. [8-K] Mereo BioPharma Group plc Reports Material Event

Mereo BioPharma (MREO) narrows Q2 2026 loss and secures alvelestat deal

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Mereo BioPharma Group plc reported second-quarter 2026 results, highlighting a smaller net loss and an extended cash runway alongside key partnering progress. Net loss for the quarter was $7.0 million, improving from $14.6 million a year earlier, driven mainly by sharply lower research and development spending.

As of June 30, 2026, cash and cash equivalents were $30.1 million, which the company expects will fund operations into late 2027. Mereo entered an option and license agreement with Sentynl Therapeutics for alvelestat, with eligibility for $40 million in upfront and R&D payments on option exercise, up to $435 million in milestones, and double-digit tiered U.S. royalties. For setrusumab, two Phase 3 studies in osteogenesis imperfecta did not meet primary fracture endpoints but showed statistically significant gains in bone mineral density and other measures, and Mereo and Ultragenyx are in regulatory discussions on a potential path forward.

Positive

  • Net loss improved to $7.0 million in Q2 2026 from $14.6 million in Q2 2025, reflecting substantially lower operating expenses.
  • Cash and cash equivalents of $30.1 million are expected to fund operations into late 2027, extending the company’s cash runway.
  • New option and license agreement for alvelestat with Sentynl includes eligibility for $40 million upfront and R&D payments, up to $435 million in milestones, and double-digit tiered U.S. royalties.

Negative

  • Setrusumab Orbit and Cosmic Phase 3 studies in osteogenesis imperfecta did not achieve statistical significance on their primary endpoints of reducing annualized clinical fracture rate.
  • Quarterly revenue fell to $0 in Q2 2026 from $0.5 million in Q2 2025, leaving the company fully loss-making.
  • Cash and cash equivalents declined to $30.1 million at June 30, 2026 from $41.0 million at December 31, 2025, despite reduced spending.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Net loss Q2 2026 $7.0 million Net loss for the three months ended June 30, 2026
Net loss Q2 2025 $14.6 million Net loss for the three months ended June 30, 2025
Cash and cash equivalents $30.1 million Balance at June 30, 2026; expected to fund operations into late 2027
R&D expenses Q2 2026 $1.8 million Research and development expenses for the three months ended June 30, 2026
R&D expenses Q2 2025 $5.4 million Research and development expenses for the three months ended June 30, 2025
Potential upfront and R&D payments $40 million Eligible on exercise of Sentynl’s option for alvelestat
Potential milestone payments $435 million Regulatory and commercial milestones under alvelestat Sentynl agreement
Ordinary shares issued 798,093,044 shares Total ordinary shares issued as of June 30, 2026
option and license agreement regulatory
"Mereo recently announced an option and license agreement with Sentynl Therapeutics"
osteogenesis imperfecta medical
"path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected"
A genetic disorder that makes bones unusually fragile because the body produces faulty or too little of the protein that gives bone its strength; think of bones like a building made from weak bricks rather than strong ones. Investors track it because treatments, diagnostics, or therapies for the condition can create markets, affect clinical trial outcomes, regulatory approvals, and potential revenue for biotech and pharmaceutical companies developing interventions.
Alpha-1 Antitrypsin Deficiency-Associated Lung Disease medical
"alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease"
A genetic condition in which the body lacks enough of a protein that protects the lungs, causing progressive lung damage and breathing problems similar to how a missing air filter lets dust gum up an engine. It matters to investors because it creates a defined group of patients and ongoing medical need, which shapes demand for treatments, the size of potential markets, clinical trial designs, regulatory decisions, and reimbursement dynamics.
Phase 3 study technical
"refine the design of the global Phase 3 study for our potential first-in-class oral therapy"
A phase 3 study is the large-scale clinical trial that tests whether a new drug or medical treatment actually works and is safe in a broad group of patients, typically after earlier smaller tests. Investors watch these studies like a final dress rehearsal because their successful completion is often required for regulatory approval and market access; positive or negative results can sharply change a company’s future sales prospects and stock value.
double-digit tiered royalties financial
"as well as double-digit tiered royalties on U.S. net sales of alvelestat"
Revenue Q2 2026 $0 Down from $0.5 million in Q2 2025
Net loss Q2 2026 $7.0 million Improved from $14.6 million in Q2 2025
R&D expenses Q2 2026 $1.8 million Down from $5.4 million in Q2 2025
G&A expenses Q2 2026 $5.2 million Slightly down from $5.5 million in Q2 2025
Cash and cash equivalents $30.1 million Down from $41.0 million at December 31, 2025
Guidance

Existing cash and cash equivalents are expected to fund currently committed clinical trials, operating expenses, and capital expenditures into late 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were Mereo BioPharma (MREO)’s key financial results for Q2 2026?
Mereo BioPharma reported a Q2 2026 net loss of $7.0 million, improved from $14.6 million a year earlier. R&D expenses fell to $1.8 million and G&A costs to $5.2 million, with $0 revenue compared to $0.5 million in Q2 2025.

How much cash does Mereo BioPharma (MREO) have and what is the runway?
As of June 30, 2026, Mereo held $30.1 million in cash and cash equivalents. Management expects this balance to fund committed clinical trials and operating needs into late 2027, excluding any additional payments from future business development transactions.

What are the main terms of Mereo BioPharma (MREO)’s alvelestat deal with Sentynl?
Mereo signed an option and license agreement granting Sentynl U.S. commercial and global manufacturing rights for alvelestat in AATD-LD. On option exercise, Mereo would be eligible for $40 million in upfront and R&D payments, up to $435 million in milestones, and double-digit tiered U.S. royalties.

What is the latest update on Mereo BioPharma (MREO)’s setrusumab program?
Two Phase 3 OI studies for setrusumab did not meet their primary fracture endpoints but showed highly significant bone mineral density improvements and favorable patient-reported outcomes. Mereo and Ultragenyx are engaging regulators, with the FDA open to alternative fracture analyses and further data discussions.

How have Mereo BioPharma (MREO)’s R&D and G&A expenses changed year over year?
Q2 2026 R&D expenses were $1.8 million, down from $5.4 million in Q2 2025, mainly from lower setrusumab and alvelestat spend. G&A expenses decreased slightly to $5.2 million from $5.5 million, driven by delayed pre-commercial investments and cost savings.

How many shares of Mereo BioPharma (MREO) are outstanding and how many ADSs?
As of June 30, 2026, Mereo had 798,093,044 ordinary shares issued. This equates to 159,618,608 American Depositary Share equivalents, with each ADS representing five ordinary shares of the company.
0001719714trueFalseX000-00000000001719714dei:AdrMember2026-08-112026-08-1100017197142026-08-112026-08-110001719714us-gaap:CommonStockMember2026-08-112026-08-11

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 11, 2026

 

MEREO BIOPHARMA GROUP PLC

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

England and Wales

 

001-38452

 

Not Applicable

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

4th Floor, One Cavendish Place,

London, W1G 0QF

United Kingdom

(Address of principal executive offices, including zip code)

 

+44-333-023-7300

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol

 

Name of each exchange on which
registered

American Depositary Shares, each representing five Ordinary Shares, par value £0.003 per share

 

MREO

 

The Nasdaq Stock Market LLC

Ordinary Shares, nominal value £0.003 per share*

 

*

 

The Nasdaq Stock Market LLC


*Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2026, Mereo BioPharma Group plc announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent corporate developments. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.


Description of Exhibit

99.1

Press Release, dated August 11, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

 

 

 

MEREO BIOPHARMA GROUP PLC

 

 

 

Date: August 11, 2026

By:

/s/ Christine Fox

 

 

Name:

Christine Fox

 

 

Title:

Chief Financial Officer

 

Exhibit 99.1

 

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights

Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

 

Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026

 

Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027

London, August 11, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate highlights.

 

The Company is also updating its previous cash runway guidance. As of June 30, 2026, cash and cash equivalents were approximately $30 million, which are expected to fund operations into late-2027.

 

“The partnership with Sentynl Therapeutics which we announced earlier today marks a significant milestone for our alvelestat program and for the Company as a whole. We are now working together to refine the design of the global Phase 3 study for our potential first-in-class oral therapy for AATD-LD and look forward to a continued close collaboration during the short option period. Assuming exercise of the license option by Sentynl, we plan to initiate the Phase 3 trial in early 2027,” said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma. “Additionally, alongside our partner Ultragenyx, we have had initial regulatory interactions on setrusumab with the FDA and the MHRA and we expect to be in a position to provide an update on the potential path forward by the end of this year. We finished the quarter with approximately $30 million in cash. Thanks to our careful expense management, we now expect that this cash will provide runway into late-2027, exclusive of the potential $40 million in upfront and R&D payments that we are eligible to receive on exercise of the alvelestat option by Sentynl.”

 

Second Quarter 2026 Highlights, Recent Developments, and Anticipated Milestones

 

Setrusumab (UX143)

•
The Orbit and the Cosmic Phase 3 studies did not achieve statistical significance against the primary endpoints of reduction in annualized clinical fracture rate, however, both achieved high statistical significance against the key secondary endpoint of improvement in bone mineral density, as well as reductions in vertebral fractures and improvements in patient reported outcomes (PROs) associated with disease severity, pain / discomfort and daily activities, with these PRO improvements achieving statistical significance in the Orbit study. Setrusumab also achieved meaningful reductions in fractures in certain bones and in patients with higher fracture frequencies. Both studies demonstrated a safety profile consistent with that observed in previous trials.
•
Mereo and its partner, Ultragenyx Pharmaceutical, Inc. (“Ultragenyx”), are engaged with regulatory agencies to determine a potential path forward for setrusumab in pediatric OI patients and, to-date, have held discussions with the regulators in the U.S. and the U.K. The FDA indicated openness to considering alternative approaches to fracture analysis, with additional conversations needed to further define what additional clinical data would be needed to support a potential BLA. In recent communications with the MHRA, they encouraged further dialogue on any future development proposal, and we plan to have further interactions following the FDA discussions.

 

Alvelestat (MPH-966)

•
Mereo recently announced an option and license agreement with Sentynl Therapeutics, Inc. (Sentynl), a wholly owned subsidiary of Zydus Lifesciences Limited. Sentynl has the right to acquire a license for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
o
Sentynl is a California-based, commercial-stage biopharmaceutical company with three currently approved products for rare diseases.
o
Under the agreement, the companies will collaborate to refine the design of the planned global Phase 3 trial of alvelestat and to advance the manufacturing during the short option period.
•
Mereo will receive a non-refundable option fee and, on option exercise, would also be eligible to receive $40 million in upfront and R&D payments, up to $435 million in regulatory and commercial milestone payments, as well as double-digit tiered royalties on U.S. net sales of alvelestat.
•
Mereo will lead the global Phase 3 study and regulatory interactions until study completion and will retain rest-of-world commercial rights for alvelestat.
•
On exercise of the option by Sentynl, the agreement provides funding for the global Phase 3 study, which could be initiated early in 2027.

 

Vantictumab (OMP18R5)

•
āshibio, Inc. (āshibio), Mereo’s development and commercial partner for vantictumab, is continuing to advance toward initiation of a Phase 2 clinical trial in autosomal dominant osteopetrosis Type 2 (ADO2).
•
āshibio is responsible for the global clinical development of vantictumab. Mereo has retained European commercial rights to the product, with āshibio holding commercial rights for the rest of the world.

 

Second Quarter 2026 Financial Results

Total research and development (“R&D”) expenses decreased by $3.6 million, from $5.4 million in the second quarter of 2025 to $1.8 million in the second quarter of 2026. The decrease was primarily due to a reduction of $2.6 million in R&D expenses for setrusumab and $1.0 million for alvelestat. The decrease in program expenses for setrusumab was primarily driven by reduction of, and delays to, investment in manufacturing and ongoing activities, including medical affairs activities in Europe during the second quarter of 2026. The decrease in program expenses for alvelestat was primarily due to completion of activities undertaken in preparation for the potential Phase 3 study during 2025.

 

General and administrative (“G&A”) expenses decreased by $0.3 million, from $5.5 million in the second quarter of 2025 to $5.2 million in the second quarter of 2026. The decrease was primarily due to reductions of approximately $2.2 million driven by delays to investment in pre-commercial activities to lay the foundation for the potential commercial launch of setrusumab in Europe and other realized cost savings. These decreases were partially offset by the recognition of a $1.9 million reduction in expenses in the second quarter of 2025 for amounts received from our depository to reimburse certain expenses incurred by us in respect of our ADR program, whereas the corresponding amount in the current year was recognized in the first quarter of 2026.

 

Net loss for the second quarter of 2026 was $7.0 million, compared to $14.6 million for the second quarter of 2025, primarily reflecting reductions in R&D and G&A expenses and a lower net foreign currency translation loss.

 

As of June 30, 2026, the Company had cash and cash equivalents of $30.1 million, compared to $41.0 million as of December 31, 2025. The Company expects, based on current operational plans, that its existing cash and cash equivalents balance will enable it to fund its currently committed clinical trials, operating expenses, and capital expenditure requirements into late 2027. This guidance does not include any future potential payments associated with business development activity around any of the Company’s programs.

 

Total ordinary shares issued as of June 30, 2026 were 798,093,044. Total ADS equivalents as of June 30, 2026 were 159,618,608, with each ADS representing five ordinary shares of the Company. 

 

About Mereo BioPharma
 

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights to commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with āshibio, Inc., for vantictumab in ADO2. āshibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

 

Forward-Looking Statements
 

This press release contains “forward-looking statements” that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company’s reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company’s dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company’s dependence on its key executives; and the Company’s ability to maintain compliance with Nasdaq continued listing requirements.

 

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,” “outlook,” “will,” “continue” and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company’s current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

 

Mereo BioPharma Contacts:

 

 

Mereo

+44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer

 

Christine Fox, Chief Financial Officer

 

 

 

Burns McClellan (Investor Relations Adviser to Mereo)

+01 646 930 4406

Lee Roth

 

Investors

investors@mereobiopharma.com

 

 

 

 

 

MEREO BIOPHARMA GROUP PLC

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

June 30,

 

 

December 31,

 

 

2026

 

 

2025

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

30,118

 

 

$

40,992

 

Prepaid expenses and other current assets

 

 

1,600

 

 

 

2,531

 

Research and development incentives receivables

 

 

1,683

 

 

 

1,497

 

Total current assets

 

 

33,401

 

 

 

45,020

 

Property and equipment, net

 

 

54

 

 

 

137

 

Operating lease right-of-use assets, net

 

 

1,003

 

 

 

244

 

Intangible assets, net

 

 

256

 

 

 

516

 

Total assets

 

$

34,714

 

 

$

45,917

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

1,121

 

 

$

1,333

 

Accrued expenses

 

 

2,455

 

 

 

2,026

 

Operating lease liabilities – current

 

 

1,030

 

 

 

202

 

Other current liabilities

 

 

1,071

 

 

 

741

 

Total current liabilities

 

 

5,677

 

 

 

4,302

 

Warrant liabilities – non-current

 

 

15

 

 

 

38

 

Other non-current liabilities

 

 

370

 

 

 

661

 

Total liabilities

 

$

6,062

 

 

$

5,001

 

 

 

 

 

 

 

 

Shareholders’ Equity

 

 

 

 

 

 

Ordinary shares, par value £0.003 per share; 798,093,044 shares issued at June 30, 2026 (December 31, 2025: 795,658,504)

 

$

3,145

 

 

$

3,135

 

Additional paid-in capital

 

 

552,335

 

 

 

549,622

 

Accumulated deficit

 

 

(514,543

)

 

 

(501,018

)

Accumulated other comprehensive loss

 

 

(12,285

)

 

 

(10,823

)

Total shareholders’ equity

 

$

28,652

 

 

$

40,916

 

Total liabilities and shareholders’ equity

 

$

34,714

 

 

$

45,917

 

 

MEREO BIOPHARMA GROUP PLC

CONDENSED CONSOLIDATED STATEMENTS

OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenue

 

$

—

 

 

$

500

 

 

$

—

 

 

$

500

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

—

 

 

 

(132

)

 

 

—

 

 

 

(132

)

Research and development

 

 

(1,808

)

 

 

(5,373

)

 

 

(6,555

)

 

 

(9,303

)

General and administrative

 

 

(5,222

)

 

 

(5,494

)

 

 

(9,241

)

 

 

(12,766

)

Loss from operations

 

 

(7,030

)

 

 

(10,499

)

 

 

(15,796

)

 

 

(21,701

)

Other income/(expenses)

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

278

 

 

 

589

 

 

 

605

 

 

 

1,248

 

Interest expense

 

 

(16

)

 

 

(24

)

 

 

(37

)

 

 

(204

)

Changes in the fair value of warrants

 

 

6

 

 

 

(101

)

 

 

23

 

 

 

315

 

Foreign currency transaction (loss)/gain, net

 

 

(362

)

 

 

(5,326

)

 

 

1,267

 

 

 

(8,091

)

Benefit from research and development tax credit

 

 

119

 

 

 

745

 

 

 

214

 

 

 

930

 

Net loss before income tax

 

 

(7,005

)

 

 

(14,616

)

 

 

(13,724

)

 

 

(27,503

)

Income tax benefit

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Net loss

 

$

(7,005

)

 

$

(14,616

)

 

$

(13,724

)

 

$

(27,503

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share – basic and diluted

 

$

(0.01

)

 

$

(0.02

)

 

$

(0.02

)

 

$

(0.03

)

Weighted average shares outstanding – basic and diluted

 

 

803,562,708

 

 

 

799,435,329

 

 

 

802,688,993

 

 

 

794,022,295

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(7,005

)

 

$

(14,616

)

 

$

(13,724

)

 

$

(27,503

)

Other comprehensive income/(loss) – Foreign currency translation adjustments, net of tax

 

 

286

 

 

 

6,647

 

 

 

(1,462

)

 

 

10,206

 

Total comprehensive loss

 

$

(6,719

)

 

$

(7,969

)

 

$

(15,186

)

 

$

(17,297

)

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

Other Documents